INKT Earnings — MiNK Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
INKT — MiNK Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$12.20
Market Cap$60.8M
P/E—
52W Range$6.80 – $76.00
Next Earnings2026-08-13
About MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
